OptimizeRx 8-K: Executive Compensation & Officer Changes
Ticker: OPRX · Form: 8-K · Filed: Jan 26, 2024 · CIK: 1448431
| Field | Detail |
|---|---|
| Company | Optimizerx CORP (OPRX) |
| Form Type | 8-K |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $40,000, $150,000, $10,000, $5,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-compensation, corporate-governance, officer-changes
TL;DR
**OptimizeRx filed an 8-K on Jan 26, 2024, detailing executive compensation changes and officer updates from Jan 24, 2024.**
AI Summary
OptimizeRx Corporation filed an 8-K on January 26, 2024, reporting an event that occurred on January 24, 2024. This filing primarily concerns changes in executive compensation arrangements, specifically related to the departure or election of certain officers, and also includes a Regulation FD Disclosure. For investors, this matters because changes in executive compensation or leadership can signal shifts in company strategy or financial health, potentially impacting future stock performance.
Why It Matters
Changes in executive compensation and officer roles can indicate strategic shifts or financial adjustments within OptimizeRx, which could influence investor confidence and the company's operational direction.
Risk Assessment
Risk Level: low — This filing is routine for reporting changes in executive compensation and officer roles, which are standard corporate governance matters and do not inherently pose a high risk.
Analyst Insight
A smart investor would monitor subsequent filings or company announcements for specific details regarding the executive compensation changes and officer appointments, as this 8-K only indicates the occurrence of such events without providing specifics.
Key Players & Entities
- OptimizeRx Corporation (company) — the registrant filing the 8-K
- United States Securities and Exchange Commission (company) — the regulatory body receiving the filing
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 24, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 26, 2024.
What specific items were disclosed in this 8-K filing?
The filing disclosed information under 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits'.
What is the trading symbol for OptimizeRx Corporation's Common Stock?
The trading symbol for OptimizeRx Corporation's Common Stock is OPRX.
In which state is OptimizeRx Corporation incorporated?
OptimizeRx Corporation is incorporated in Nevada.
Filing Stats: 753 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-01-26 16:00:20
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value OPRX The Nasdaq Capital M
- $40,000 — ther things, an annual cash retainer of $40,000, an annual equity grant with a grant da
- $150,000 — ith a grant date value of approximately $150,000, an additional annual cash retainer of
- $10,000 — , an additional annual cash retainer of $10,000 for serving as an Audit Committee Membe
- $5,000 — d an additional annual cash retainer of $5,000 for serving as a Compensation Committee
Filing Documents
- ea192296-8k_optimizerx.htm (8-K) — 26KB
- ea192296ex99-1_optimizerx.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-24-006959.txt ( ) — 227KB
- oprx-20240124.xsd (EX-101.SCH) — 3KB
- oprx-20240124_lab.xml (EX-101.LAB) — 33KB
- oprx-20240124_pre.xml (EX-101.PRE) — 22KB
- ea192296-8k_optimizerx_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPTIMIZERX CORPORATION Date: January 26, 2024 By: /s/ Edward Stelmakh Name: Edward Stelmakh Title: Chief Financial Officer 2